Gül Özdemir - Academia.edu (original) (raw)
Papers by Gül Özdemir
Turkish Journal of Hematology
Turkish Journal of Analytical Chemistry
A series of 3-alkyl(aryl)-4-[3-(2-metylbenzoxy)-4-methoxybenzylideneamino]-4,5-dihydro-1H-1,2,4-t... more A series of 3-alkyl(aryl)-4-[3-(2-metylbenzoxy)-4-methoxybenzylideneamino]-4,5-dihydro-1H-1,2,4-triazol-5-ones (1-9) were titrated potentiometrically with tetrabutylammonium hydroxide in four non-aqueous solvents such as isopropyl alcohol, tert-butyl alcohol, acetonitrile, and N,N-dimethylformamide (DMF), and graphs were drawn for all cases. The half-neutralization potential values and the corresponding pKa values were determined by the half neutralization method. Thus, the effects of solvents and molecular structure upon acidity were discussed.
Journal of Glaucoma and Cataract, 2022
Turkish Journal of Hematology, 2022
Amaç: Anjiyofolliküler lenf nodu hiperplazisi olarak da bilinen Castleman hastalığı (CH), nadir b... more Amaç: Anjiyofolliküler lenf nodu hiperplazisi olarak da bilinen Castleman hastalığı (CH), nadir bir hastalık olup başlıca hiyalin vasküler ve plazma hücreli olmak üzere 2 histolojik alt tipi vardır. Hastalığın anatomik yayılımı ve tutulan lenf nodu bölgelerinin sayısına göre unisentrik (UCH) ya da multisentrik (MCH) olarak sınıflandırılır. Bu çok merkezli çalışmanın amacı bugüne kadar Türkiye'de tanımlanan tüm CH olgularını tanımlamak, ulusal bir veri tabanı oluşturarak CH'de erken tanı, tedavi ve takip sürecine katkı sağlamaktır. Objective: Castleman disease (CD) is a rare disease also known as angiofollicular lymph node hyperplasia. The two main histological subtypes are the hyaline vascular and plasma cell variants. It is further classified as unicentric CD (UCD) or multicentric CD (MCD) according to the anatomical distribution of the disease and the number of lymph nodes involved. The aim of this multicenter study was to evaluate all cases of CD identified to date in Turkey to set up a national registry to improve the early recognition, treatment, and follow-up of CD.
İstanbul Kanuni Sultan Süleyman Tıp Dergisi, 2021
Objective: This study aimed to evaluate the acute toxicity, overall survival (OS), and event-free... more Objective: This study aimed to evaluate the acute toxicity, overall survival (OS), and event-free survival (EFS) of children diagnosed and treated for acute myeloid leukemia. Method: This study includes a total of 43 patients (age range: 1-18 years) who were diagnosed and treated from 2011 to 2016 at a pediatric hematology and oncology clinic at a teaching hospital in Turkey. The patient files were retrospectively analyzed. Results: Of the 43 patients, 22 (51.2%) were boys and 21 (48.8%) were girls. The mean age at the time of diagnosis was 7.39 ± 4.7 years. Fourteen (32.6%) patients were classified as standard-risk, 15 (34.9%) intermediate-risk, and 11(25.6%) high-risk group. Information about risk groups of three patients was missing in the medical records. Two patients were lost due to acute toxicity and four were lost due to infection after induction therapy. Bone marrow relapse occurred in three (6.9%) patients who had completed induction therapy and had bone marrow remission. The median follow-up period was 29 months (range: 1-74 months). The estimated 5-year OS and EFS were found to be 76% ± 6.6% and 66% ± 9.3%, respectively. The estimated 2-year OS for standard, intermediate, and high-risk groups was 77% ± 12%, 77% ± 10%, and 82% ± 12%, respectively, while EFS was 77% ± 12%, 70% ± 11%, and 73% ± 13%, respectively (p > 0.05). Conclusion: The OS and EFS were positively favored with the current median follow-up. The study should be repeated with more patients and longer follow-up periods.
In this study, six new 1-(2,6-dimethylmorpholin-4-yl-methyl)-3-alkyl(aryl)-4-[3-ethoxy-(4- benzen... more In this study, six new 1-(2,6-dimethylmorpholin-4-yl-methyl)-3-alkyl(aryl)-4-[3-ethoxy-(4- benzenesulfonyloxy)-benzylideneamino]-4,5-dihydro-1 H -1,2,4-triazol-5-ones were obtained from the reactions of 3-alkyl(aryl)-4-[3-ethoxy-(4-benzenesulfonyloxy)-benzylideneamino]-4,5-dihydro-1 H -1,2,4-triazol-5-ones with 2,6-dimethylmorpholine and formaldehyde. Characterization of new compounds obtained was carried out by IR, 1 H-NMR, 13 C-NMR spectral data. Antibacterial properties of the synthesized novel compounds were evaluated by agar well method against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus subtilis, Bacillus cereus and Klepsiella pneumoniae strains.
In this study, theoretically spectral values of 1-methyl-3-benzyl-4-(3-ethoxy-4-methoxybenzyliden... more In this study, theoretically spectral values of 1-methyl-3-benzyl-4-(3-ethoxy-4-methoxybenzylidenamino)-4,5-dihydro- 1H -1,2,4-triazol-5-one were calculated and these values were compared with experimental values and obtained conclusions were evaluated. For this purpose, firstly, 1-methyl-3-benzyl-4-(3-ethoxy-4-methoxybenzylidenamino)-4,5-dihydro-1 H -1,2,4-triazol-5-one has been optimized using B3LYP/6-311G(d,p) and HF/6-311G(d,p) basis set. 1 H-NMR and 13 C-NMR spectral values according to GIAO method was calculated using Gaussian G09W program package in gas phase and in DMSO solvent. Theoretically and experimentally values were plotted according to δ exp=a. δ calc. + b, Eq. a and b constants regression coefficients with a standard error values were found using the Sigma plot program. Theoretically calculated IR values of this compound were calculated in gas phase by using of 6-311G(d,p) basis sets of B3LYP and HF methods and are multiplied with appropriate scale factors and the v...
1İstanbul University Cerrahpaşa Medical Faculty, Department of Pediatrics, Istanbul, Turkey 2İsta... more 1İstanbul University Cerrahpaşa Medical Faculty, Department of Pediatrics, Istanbul, Turkey 2İstanbul University Cerrahpaşa Medical Faculty, Division of Pediatric Hematology-Oncology, Istanbul, Turkey 3İstanbul University Cerrahpaşa Medical Faculty, Division of Pediatric Endocrinology, Istanbul, Turkey 4İstanbul University Cerrahpaşa Medical Faculty, Division of Pediatric Cardiology, İstanbul, Turkey
European Journal of Science and Technology, 2020
Öz 1,2,4-Triazol ve 4,5-dihidro-1H-1,2,4-triazol-5-on halkası taşıyan heterosiklik bileşikler çok... more Öz 1,2,4-Triazol ve 4,5-dihidro-1H-1,2,4-triazol-5-on halkası taşıyan heterosiklik bileşikler çok geniş bir spektrumda biyolojik aktivite göstermektedir. Schiff bazlarının ise boya, tekstil, kozmetik, analitik reaktifler, su iyileştirme ürünleri, petrol katkı maddeleri, sentetik polimer ürünleri, deri ve kağıt gibi doğal makromoleküler materyallerin iyileştirilmesi gibi çeşitli pratik uygulamaları bulunmaktadır. Ancak Schiff Bazlarının en önemli uygulama alanı ilaç kimyasıdır. Potansiyel biyolojik aktif 1,2,4-triazol halkası içeren Schiff bazlarının birçok hastalığın tedavisinde kullanılabilecek faydalı moleküllerin ve ileride hastalıkların tedavisinde kullanılabilecek ilaçların elde edilmesi ümit edilmektedir. Bu amaçla 3-alkil(aril)-4-amino-4,5-dihidro-1H-1,2,4-triazol-5-on'ların (1), 2-formil-6metoksifenil furan-2-karboksilat (2) ile reaksiyonundan 2-metoksi-6-[(3-alkil/aril-4,5-dihidro-1H-1,2,4-triazol-5-on-4-il)azometin]fenil furan-2-karboksilatlar (3) elde edilmiştir. Daha sonra 3 bileşiklerinin asetilasyon reaksiyonları incelenerek 2-metoksi-6-[(1-asetil-3-alkil/aril-4,5-dihidro-1H-1,2,4-triazol-5-on-4-il)-azometin]fenil furan-2-karboksilatlar (4) sentezlenmiştir. On dört yeni bileşiğin yapıları IR, 1 H NMR, 13 C NMR ve UV spektral verileri kullanılarak aydınlatılmıştır. Ayrıca, sentezlenen 3 ve 4 tipi yeni bileşiklerin üç farklı yöntemle (indirgeme gücü, serbest radikal giderme aktivitesi ve metal şelat aktivitesi) in vitro antioksidan özellikleri değerlendirilmiştir.
Turkish Journal of Analytical Chemistry, 2021
In this study, to determine the pKa values of 2-ethoxy-6-(3-substitue-4,5-dihydro-1H-1,2,4-triazo... more In this study, to determine the pKa values of 2-ethoxy-6-(3-substitue-4,5-dihydro-1H-1,2,4-triazol-5-one-4-yl-azomethine)-phenyl benzoates (1-9) were titrated potentiometrically with tetrabutylammonium hydroxide in four non-aqueous solvents such as isopropyl alcohol, tert-butyl alcohol, acetone and N,N-dimethylformamide (DMF), and graphs were drawn for all cases. In addition, the effects of solvents and molecular structure upon acidity compounds 1-9 were also determined and discussed. The half-neutralization potential values and the corresponding pKa values were determined by the half neutralization method.
A series of new 1,3,5-tri-{4-[(3-alkyl/aryl-4,5-dihydro-1H-1,2,4-triazol-5-one-4-yl)-azomethin]ph... more A series of new 1,3,5-tri-{4-[(3-alkyl/aryl-4,5-dihydro-1H-1,2,4-triazol-5-one-4-yl)-azomethin]phenoxycarbonyl} benzenes (4) were obtained from the reactions of 3-alkyl/aryl-4-amino-4,5-dihydro-1H-1,2,4triazol-5-ones (2) with 1,3,5-tri-(4-formylphenoxycarbonyl)-benzene (1) and characterized by IR, 1 H-NMR and 13 CNMR spectral data. In addition, to investigate the effects of solvents and molecular structure upon acidity, the new nine compounds 4 were titrated potentiometrically with tetrabutylammonium hydroxide in four non-aqueous solvents (isopropyl alcohol, tert-butyl alcohol, N,N-dimethylformamide and acetone). The half-neutralization potential values and the corresponding pKa values were determined for all cases.
Bilesik B3LYP/6311G (d,p) ve HF/6311G (d,p) temel setleri kullanilarak optimize edilmistir. 1 H-N... more Bilesik B3LYP/6311G (d,p) ve HF/6311G (d,p) temel setleri kullanilarak optimize edilmistir. 1 H-NMR ve 13 C-NMR isotropic kayma degerleri Gaussian G09W paket programi kullanilarak GIAO metodu ile hesaplanmistir. Deneysel ve teorik degerler δ exp=a+b. δ calc. esitligine gore grafige gecirilmis tir. Standart hata degerleri a ve b sabitleri nin regresyon katsayisi ile Sigmaplot programi kullanilarak bulunmustur. Analiz edilen molekullerin IR absorbsiyon frekanslari iki metod ile hesaplanmistir. Veda 4f programi teorik hesaplamada IR verilerini belirlemede kullanilmistir. Deneysel ve elde edilen teorik degerler karsilastirilmis ve regresyon analizi ile bulunan degerleri dogrulamistir. 3-( p -metilbenzil) -4-kloroasetilamino-4,5-dihidro-1 H -1,2,4-triazol-5-on molekulunun deneysel spektroskopik verileri literaturde tanimlanmistir.
A 13 months old male patient was hospitalized with a diagnosis of reactive airway disease because... more A 13 months old male patient was hospitalized with a diagnosis of reactive airway disease because of frequently recurring attacks of bronchiolitis and started to be treated. In his history, it was learned that the parents were healthy and had third degree consanguinity between each other. The patient was dignosed as right renal atrophy prenatally and was operated postnatally when he was 9 days old because of anal atresia and uretherocele. Physicial examination revealed the following: height 80 cm (50-75th percentile), weight 11.5 kg (75th percentile), blood pressure: 100/55 mmHg, heart rate:110/min, respiratory rate: 44/min, body temperature: 37.5°C. Wheezing was heard on oscultation of the lungs and the patient had respiratory distress. Intercostal and subcostal retractions were observed. Seven fingers were present in the right hand and 6 fingers were present in both lower extremities. Examination of the other systems was normal. On the posteroanterior chest graphy, bilateral incre...
Pediatric Hematology and Oncology, 2021
Abstract This study was organized to determine the efficacy and safety of deferasirox (DFX) in re... more Abstract This study was organized to determine the efficacy and safety of deferasirox (DFX) in reducing the SF of patients with transfusion-dependent thalassemia (TDT). This is a retrospective, descriptive study of 101 transfusion- dependent patients with thalassemia major who were followed for 48 months. Twenty-nine patients who used an alternative chelator either alone or combined, who were not compliant to the treatment, changed the drug due to adverse reactions, and had multiple transfusions and did not complete 4 years of DFX use were excluded. A total 72 out of 101 patients completed the study. SF decreases were noted for the 6-12 and >18-year age groups, from a median of 1532 ng/mL to 1190 ng/mL, and from 1386 ng/mL to 1165 ng/mL, respectively (p > 0.05). The proportion of patients with SF concentrations >2000 ng/mL is decreased (29% at baseline decreased to 15% at the end of the study) during the 48 months. The median SF of those who used <30 mg/kg/day (n = 38) increased from 767 ng/mL to 1006 ng/mL, whereas the >30 mg/kg/day (n = 34) group’s SF concentrations decreased from a median of 1575 ng/mL to 1209 ng/mL (p = 0.029). The decrease of median SF values for Syrian patients was statistically significant (p = 0.043). Most common adverse events were gastric irritation symptoms (19.4%). The total DFX discontinuation ratio was calculated as 9.7%. Although dosages between 25-30 mg/kg/day are adequate to stabilize SF concentrations higher dosages are needed to achieve a statistically significant decrease.
International Journal of Laboratory Hematology, 2020
Microtubules are polymers that perform functions such as mitosis, intracellular transport, cell m... more Microtubules are polymers that perform functions such as mitosis, intracellular transport, cell morphology, and ciliary and flagellar motility. Since microtubules are taking active part in cell division, they are among direct targets of several antimitotic drugs.
Turkish Journal of Hematology, 2020
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder ch... more Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis or petechiae. The thrombopoietin receptor agonist, eltrombopag is second-line agents used to treat chronic immune thrombocytopenia purpura in adults and children. Methods: The aim of the present study was to evaluate the efficacy, safety and side effects, especially iron deficiency of eltrombopag treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 ± 4.5 years (1.2-18 years) at the beginning of EPAG treatment. Overall response rate was 74.3 %(n:78). The mean time for Plt count ≥50×10 9 /L was 11.6 ±8 weeks (range 1-34 weeks). The treatment was stopped in 27 patients (25.7%) on an average of 6.8±9 months (range 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects especially iron deficiency during treatment.
Asian Journal of Chemical Sciences, 2018
This work was carried out in collaboration between all authors. Author HY designed the study, man... more This work was carried out in collaboration between all authors. Author HY designed the study, managed the literature searches and interpreted all spectroscopic and experimental results. Author GK wrote the protocol and performed all theoretical studies. Author GO wrote the first draft of the manuscript and interpreted the theoretical results of the study. All authors read and approved the final manuscript.
Pediatric Hematology Oncology Journal, 2019
This is a PDF file of an article that has undergone enhancements after acceptance, such as the ad... more This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Turkish Journal of Hematology
Turkish Journal of Analytical Chemistry
A series of 3-alkyl(aryl)-4-[3-(2-metylbenzoxy)-4-methoxybenzylideneamino]-4,5-dihydro-1H-1,2,4-t... more A series of 3-alkyl(aryl)-4-[3-(2-metylbenzoxy)-4-methoxybenzylideneamino]-4,5-dihydro-1H-1,2,4-triazol-5-ones (1-9) were titrated potentiometrically with tetrabutylammonium hydroxide in four non-aqueous solvents such as isopropyl alcohol, tert-butyl alcohol, acetonitrile, and N,N-dimethylformamide (DMF), and graphs were drawn for all cases. The half-neutralization potential values and the corresponding pKa values were determined by the half neutralization method. Thus, the effects of solvents and molecular structure upon acidity were discussed.
Journal of Glaucoma and Cataract, 2022
Turkish Journal of Hematology, 2022
Amaç: Anjiyofolliküler lenf nodu hiperplazisi olarak da bilinen Castleman hastalığı (CH), nadir b... more Amaç: Anjiyofolliküler lenf nodu hiperplazisi olarak da bilinen Castleman hastalığı (CH), nadir bir hastalık olup başlıca hiyalin vasküler ve plazma hücreli olmak üzere 2 histolojik alt tipi vardır. Hastalığın anatomik yayılımı ve tutulan lenf nodu bölgelerinin sayısına göre unisentrik (UCH) ya da multisentrik (MCH) olarak sınıflandırılır. Bu çok merkezli çalışmanın amacı bugüne kadar Türkiye'de tanımlanan tüm CH olgularını tanımlamak, ulusal bir veri tabanı oluşturarak CH'de erken tanı, tedavi ve takip sürecine katkı sağlamaktır. Objective: Castleman disease (CD) is a rare disease also known as angiofollicular lymph node hyperplasia. The two main histological subtypes are the hyaline vascular and plasma cell variants. It is further classified as unicentric CD (UCD) or multicentric CD (MCD) according to the anatomical distribution of the disease and the number of lymph nodes involved. The aim of this multicenter study was to evaluate all cases of CD identified to date in Turkey to set up a national registry to improve the early recognition, treatment, and follow-up of CD.
İstanbul Kanuni Sultan Süleyman Tıp Dergisi, 2021
Objective: This study aimed to evaluate the acute toxicity, overall survival (OS), and event-free... more Objective: This study aimed to evaluate the acute toxicity, overall survival (OS), and event-free survival (EFS) of children diagnosed and treated for acute myeloid leukemia. Method: This study includes a total of 43 patients (age range: 1-18 years) who were diagnosed and treated from 2011 to 2016 at a pediatric hematology and oncology clinic at a teaching hospital in Turkey. The patient files were retrospectively analyzed. Results: Of the 43 patients, 22 (51.2%) were boys and 21 (48.8%) were girls. The mean age at the time of diagnosis was 7.39 ± 4.7 years. Fourteen (32.6%) patients were classified as standard-risk, 15 (34.9%) intermediate-risk, and 11(25.6%) high-risk group. Information about risk groups of three patients was missing in the medical records. Two patients were lost due to acute toxicity and four were lost due to infection after induction therapy. Bone marrow relapse occurred in three (6.9%) patients who had completed induction therapy and had bone marrow remission. The median follow-up period was 29 months (range: 1-74 months). The estimated 5-year OS and EFS were found to be 76% ± 6.6% and 66% ± 9.3%, respectively. The estimated 2-year OS for standard, intermediate, and high-risk groups was 77% ± 12%, 77% ± 10%, and 82% ± 12%, respectively, while EFS was 77% ± 12%, 70% ± 11%, and 73% ± 13%, respectively (p > 0.05). Conclusion: The OS and EFS were positively favored with the current median follow-up. The study should be repeated with more patients and longer follow-up periods.
In this study, six new 1-(2,6-dimethylmorpholin-4-yl-methyl)-3-alkyl(aryl)-4-[3-ethoxy-(4- benzen... more In this study, six new 1-(2,6-dimethylmorpholin-4-yl-methyl)-3-alkyl(aryl)-4-[3-ethoxy-(4- benzenesulfonyloxy)-benzylideneamino]-4,5-dihydro-1 H -1,2,4-triazol-5-ones were obtained from the reactions of 3-alkyl(aryl)-4-[3-ethoxy-(4-benzenesulfonyloxy)-benzylideneamino]-4,5-dihydro-1 H -1,2,4-triazol-5-ones with 2,6-dimethylmorpholine and formaldehyde. Characterization of new compounds obtained was carried out by IR, 1 H-NMR, 13 C-NMR spectral data. Antibacterial properties of the synthesized novel compounds were evaluated by agar well method against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus subtilis, Bacillus cereus and Klepsiella pneumoniae strains.
In this study, theoretically spectral values of 1-methyl-3-benzyl-4-(3-ethoxy-4-methoxybenzyliden... more In this study, theoretically spectral values of 1-methyl-3-benzyl-4-(3-ethoxy-4-methoxybenzylidenamino)-4,5-dihydro- 1H -1,2,4-triazol-5-one were calculated and these values were compared with experimental values and obtained conclusions were evaluated. For this purpose, firstly, 1-methyl-3-benzyl-4-(3-ethoxy-4-methoxybenzylidenamino)-4,5-dihydro-1 H -1,2,4-triazol-5-one has been optimized using B3LYP/6-311G(d,p) and HF/6-311G(d,p) basis set. 1 H-NMR and 13 C-NMR spectral values according to GIAO method was calculated using Gaussian G09W program package in gas phase and in DMSO solvent. Theoretically and experimentally values were plotted according to δ exp=a. δ calc. + b, Eq. a and b constants regression coefficients with a standard error values were found using the Sigma plot program. Theoretically calculated IR values of this compound were calculated in gas phase by using of 6-311G(d,p) basis sets of B3LYP and HF methods and are multiplied with appropriate scale factors and the v...
1İstanbul University Cerrahpaşa Medical Faculty, Department of Pediatrics, Istanbul, Turkey 2İsta... more 1İstanbul University Cerrahpaşa Medical Faculty, Department of Pediatrics, Istanbul, Turkey 2İstanbul University Cerrahpaşa Medical Faculty, Division of Pediatric Hematology-Oncology, Istanbul, Turkey 3İstanbul University Cerrahpaşa Medical Faculty, Division of Pediatric Endocrinology, Istanbul, Turkey 4İstanbul University Cerrahpaşa Medical Faculty, Division of Pediatric Cardiology, İstanbul, Turkey
European Journal of Science and Technology, 2020
Öz 1,2,4-Triazol ve 4,5-dihidro-1H-1,2,4-triazol-5-on halkası taşıyan heterosiklik bileşikler çok... more Öz 1,2,4-Triazol ve 4,5-dihidro-1H-1,2,4-triazol-5-on halkası taşıyan heterosiklik bileşikler çok geniş bir spektrumda biyolojik aktivite göstermektedir. Schiff bazlarının ise boya, tekstil, kozmetik, analitik reaktifler, su iyileştirme ürünleri, petrol katkı maddeleri, sentetik polimer ürünleri, deri ve kağıt gibi doğal makromoleküler materyallerin iyileştirilmesi gibi çeşitli pratik uygulamaları bulunmaktadır. Ancak Schiff Bazlarının en önemli uygulama alanı ilaç kimyasıdır. Potansiyel biyolojik aktif 1,2,4-triazol halkası içeren Schiff bazlarının birçok hastalığın tedavisinde kullanılabilecek faydalı moleküllerin ve ileride hastalıkların tedavisinde kullanılabilecek ilaçların elde edilmesi ümit edilmektedir. Bu amaçla 3-alkil(aril)-4-amino-4,5-dihidro-1H-1,2,4-triazol-5-on'ların (1), 2-formil-6metoksifenil furan-2-karboksilat (2) ile reaksiyonundan 2-metoksi-6-[(3-alkil/aril-4,5-dihidro-1H-1,2,4-triazol-5-on-4-il)azometin]fenil furan-2-karboksilatlar (3) elde edilmiştir. Daha sonra 3 bileşiklerinin asetilasyon reaksiyonları incelenerek 2-metoksi-6-[(1-asetil-3-alkil/aril-4,5-dihidro-1H-1,2,4-triazol-5-on-4-il)-azometin]fenil furan-2-karboksilatlar (4) sentezlenmiştir. On dört yeni bileşiğin yapıları IR, 1 H NMR, 13 C NMR ve UV spektral verileri kullanılarak aydınlatılmıştır. Ayrıca, sentezlenen 3 ve 4 tipi yeni bileşiklerin üç farklı yöntemle (indirgeme gücü, serbest radikal giderme aktivitesi ve metal şelat aktivitesi) in vitro antioksidan özellikleri değerlendirilmiştir.
Turkish Journal of Analytical Chemistry, 2021
In this study, to determine the pKa values of 2-ethoxy-6-(3-substitue-4,5-dihydro-1H-1,2,4-triazo... more In this study, to determine the pKa values of 2-ethoxy-6-(3-substitue-4,5-dihydro-1H-1,2,4-triazol-5-one-4-yl-azomethine)-phenyl benzoates (1-9) were titrated potentiometrically with tetrabutylammonium hydroxide in four non-aqueous solvents such as isopropyl alcohol, tert-butyl alcohol, acetone and N,N-dimethylformamide (DMF), and graphs were drawn for all cases. In addition, the effects of solvents and molecular structure upon acidity compounds 1-9 were also determined and discussed. The half-neutralization potential values and the corresponding pKa values were determined by the half neutralization method.
A series of new 1,3,5-tri-{4-[(3-alkyl/aryl-4,5-dihydro-1H-1,2,4-triazol-5-one-4-yl)-azomethin]ph... more A series of new 1,3,5-tri-{4-[(3-alkyl/aryl-4,5-dihydro-1H-1,2,4-triazol-5-one-4-yl)-azomethin]phenoxycarbonyl} benzenes (4) were obtained from the reactions of 3-alkyl/aryl-4-amino-4,5-dihydro-1H-1,2,4triazol-5-ones (2) with 1,3,5-tri-(4-formylphenoxycarbonyl)-benzene (1) and characterized by IR, 1 H-NMR and 13 CNMR spectral data. In addition, to investigate the effects of solvents and molecular structure upon acidity, the new nine compounds 4 were titrated potentiometrically with tetrabutylammonium hydroxide in four non-aqueous solvents (isopropyl alcohol, tert-butyl alcohol, N,N-dimethylformamide and acetone). The half-neutralization potential values and the corresponding pKa values were determined for all cases.
Bilesik B3LYP/6311G (d,p) ve HF/6311G (d,p) temel setleri kullanilarak optimize edilmistir. 1 H-N... more Bilesik B3LYP/6311G (d,p) ve HF/6311G (d,p) temel setleri kullanilarak optimize edilmistir. 1 H-NMR ve 13 C-NMR isotropic kayma degerleri Gaussian G09W paket programi kullanilarak GIAO metodu ile hesaplanmistir. Deneysel ve teorik degerler δ exp=a+b. δ calc. esitligine gore grafige gecirilmis tir. Standart hata degerleri a ve b sabitleri nin regresyon katsayisi ile Sigmaplot programi kullanilarak bulunmustur. Analiz edilen molekullerin IR absorbsiyon frekanslari iki metod ile hesaplanmistir. Veda 4f programi teorik hesaplamada IR verilerini belirlemede kullanilmistir. Deneysel ve elde edilen teorik degerler karsilastirilmis ve regresyon analizi ile bulunan degerleri dogrulamistir. 3-( p -metilbenzil) -4-kloroasetilamino-4,5-dihidro-1 H -1,2,4-triazol-5-on molekulunun deneysel spektroskopik verileri literaturde tanimlanmistir.
A 13 months old male patient was hospitalized with a diagnosis of reactive airway disease because... more A 13 months old male patient was hospitalized with a diagnosis of reactive airway disease because of frequently recurring attacks of bronchiolitis and started to be treated. In his history, it was learned that the parents were healthy and had third degree consanguinity between each other. The patient was dignosed as right renal atrophy prenatally and was operated postnatally when he was 9 days old because of anal atresia and uretherocele. Physicial examination revealed the following: height 80 cm (50-75th percentile), weight 11.5 kg (75th percentile), blood pressure: 100/55 mmHg, heart rate:110/min, respiratory rate: 44/min, body temperature: 37.5°C. Wheezing was heard on oscultation of the lungs and the patient had respiratory distress. Intercostal and subcostal retractions were observed. Seven fingers were present in the right hand and 6 fingers were present in both lower extremities. Examination of the other systems was normal. On the posteroanterior chest graphy, bilateral incre...
Pediatric Hematology and Oncology, 2021
Abstract This study was organized to determine the efficacy and safety of deferasirox (DFX) in re... more Abstract This study was organized to determine the efficacy and safety of deferasirox (DFX) in reducing the SF of patients with transfusion-dependent thalassemia (TDT). This is a retrospective, descriptive study of 101 transfusion- dependent patients with thalassemia major who were followed for 48 months. Twenty-nine patients who used an alternative chelator either alone or combined, who were not compliant to the treatment, changed the drug due to adverse reactions, and had multiple transfusions and did not complete 4 years of DFX use were excluded. A total 72 out of 101 patients completed the study. SF decreases were noted for the 6-12 and >18-year age groups, from a median of 1532 ng/mL to 1190 ng/mL, and from 1386 ng/mL to 1165 ng/mL, respectively (p > 0.05). The proportion of patients with SF concentrations >2000 ng/mL is decreased (29% at baseline decreased to 15% at the end of the study) during the 48 months. The median SF of those who used <30 mg/kg/day (n = 38) increased from 767 ng/mL to 1006 ng/mL, whereas the >30 mg/kg/day (n = 34) group’s SF concentrations decreased from a median of 1575 ng/mL to 1209 ng/mL (p = 0.029). The decrease of median SF values for Syrian patients was statistically significant (p = 0.043). Most common adverse events were gastric irritation symptoms (19.4%). The total DFX discontinuation ratio was calculated as 9.7%. Although dosages between 25-30 mg/kg/day are adequate to stabilize SF concentrations higher dosages are needed to achieve a statistically significant decrease.
International Journal of Laboratory Hematology, 2020
Microtubules are polymers that perform functions such as mitosis, intracellular transport, cell m... more Microtubules are polymers that perform functions such as mitosis, intracellular transport, cell morphology, and ciliary and flagellar motility. Since microtubules are taking active part in cell division, they are among direct targets of several antimitotic drugs.
Turkish Journal of Hematology, 2020
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder ch... more Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis or petechiae. The thrombopoietin receptor agonist, eltrombopag is second-line agents used to treat chronic immune thrombocytopenia purpura in adults and children. Methods: The aim of the present study was to evaluate the efficacy, safety and side effects, especially iron deficiency of eltrombopag treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 ± 4.5 years (1.2-18 years) at the beginning of EPAG treatment. Overall response rate was 74.3 %(n:78). The mean time for Plt count ≥50×10 9 /L was 11.6 ±8 weeks (range 1-34 weeks). The treatment was stopped in 27 patients (25.7%) on an average of 6.8±9 months (range 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects especially iron deficiency during treatment.
Asian Journal of Chemical Sciences, 2018
This work was carried out in collaboration between all authors. Author HY designed the study, man... more This work was carried out in collaboration between all authors. Author HY designed the study, managed the literature searches and interpreted all spectroscopic and experimental results. Author GK wrote the protocol and performed all theoretical studies. Author GO wrote the first draft of the manuscript and interpreted the theoretical results of the study. All authors read and approved the final manuscript.
Pediatric Hematology Oncology Journal, 2019
This is a PDF file of an article that has undergone enhancements after acceptance, such as the ad... more This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.